Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres have signed a Memorandum of Understanding (MoU) to collaborate on enhancing the capabilities of thousands of healthcare professionals in Vietnam. The two-year partnership aims to improve healthcare quality by providing education and training activities, both offline and online, related to disease awareness, prevention, and treatment options. The key priorities of the collaboration include updating healthcare professionals on the latest evidence on disease burden, clinical trials, and preventive treatment for critical respiratory illnesses and serious infections.
Respiratory infections remain a significant public health threat in Vietnam, with many diseases sharing similar early symptoms, leading to misdiagnosis or complacency. This is particularly dangerous for infants and the elderly, who are more vulnerable to severe progression once infected. Pharmacists play a crucial role in helping communities identify symptoms, provide first care advice, and reduce the burden on the healthcare system.
The collaboration between Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres marks a significant step forward in integrating global pharmaceutical expertise with the local healthcare system, aiming to raise healthcare quality to international standards. Darrell Oh, General Director of Pfizer Vietnam, emphasized the company’s long-term commitment to improving healthcare quality in Vietnam, while Nguyen Do Quyen, Deputy CEO of FPT Retail and COO of Long Chau Pharmacy and Vaccination Centres, highlighted the synergy of capabilities and alignment of vision between the two parties.
The partnership will also focus on upgrading real-world data on prevention and treatment, especially for patients with non-communicable chronic diseases, to develop an educational documentation system for Long Chau’s AI platform. This will enable healthcare professionals to access information effectively and provide better care for patients. With Pfizer’s scientific expertise and innovation, combined with Long Chau’s extensive distribution network and team of highly qualified pharmacists and doctors, the collaboration is expected to drive positive, practical, and sustainable changes for Vietnam’s healthcare system.
In related news, Pfizer has announced the final-stage trial of its two-in-one flu and COVID-19 jab, as well as the finalization of phase-three trials for its mRNA vaccine against influenza for adults. The company has also organized scientific symposia to discuss pneumococcal disease in adults and preventive measures, and has been recognized as one of the best places to work in the pharma sector. These developments demonstrate Pfizer’s commitment to improving healthcare quality and investing in healthcare human resources, both globally and in Vietnam.